High Cost of Cell Analysis Is Expected In Cell Counting Market

The market growth is largely driven by factors such as growing to fund for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers. 

 The medical application segment will grow at the highest CAGR in the cell counting market. Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.  

The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization. 

For More information Download the PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728

The hospitals and diagnostic laboratories will grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies. 

Key Market Players

cell counting

The consumables segment dominated the market in 2019 and is also expected to be the fastest-growing segment during the forecast period. By type, the media, sera, and reagents segment accounted for the largest share of the cell counting consumables market in 2019. The large share and high growth of the consumables segment can primarily be attributed to the frequent purchase of these products as compared to instruments, which are considered one-time investments. 

Research Developments:

1. In 2020, Danaher (US) acquired the Biopharma business of GE Life Sciences, GE Healthcare. This business will be established as a standalone operating company with Danaher’s Life Science segment.

2. In 2019, Agilent Technologies acquired BioTek Instruments, Inc. (US). This acquisition will strengthen Agilent Technologies' position in the cell counting market.

3. In 2019, Perkin Elmer entered into an agreement with Accenture to join Accenture’s Open Partner Ecosystem Program to help researchers accelerate drug discovery and improve patient outcomes.

4.7 Star App Store Review!
The Communities are great you rarely see anyone get in to an argument :)
Love Love LOVE

Select Collections